The profound, long-term therapeutic responses reported for TrkA fusion oncogene-driven cancers to Trk inhibitory therapy, highlights the need to better identify cancers driven by TrkA oncogenes, including TrkA oncogenes activated by aberrant alternative TrkA splicing, such as TrkAIII. The gene discussed is NTRK1; the disease is cancer.